
- Oncology NEWS International Vol 4 No 4
- Volume 4
- Issue 4
Two New Dilaudid Dosage Forms Are Available From Knoll
WHIPPANY, NJ--Two new forms of Dilaudid (hydromorphone HCL)-- Dilaudid 8 mg tablets and Dilaudid-5 Oral Liquid--are now available from Knoll Pharmaceutical Company.
WHIPPANY, NJ--Two new forms of Dilaudid (hydromorphone HCL)--Dilaudid 8 mg tablets and Dilaudid-5 Oral Liquid--are now availablefrom Knoll Pharmaceutical Company.
The 8 mg tablets allow easy titration to a higher hydromorphonedose and are more convenient for patients currently taking twoDilaudid 4 mg tablets per dose, the manufacturer said.
Dilaudid-5 Oral Liquid is designed for patients who have difficultyswallowing solid medications. One teaspoon contains 5 mg of hydromorphoneper 5 mL. The liquid is alcohol-free, colorless, unflavored, andcan be mixed with fruit juice, according to Knoll.
In addition, Knoll is making available a pocket guide "Strategiesfor Cancer Pain Management," written by Ada Rogers, RN, researchassociate and clinical coordinator of the Pain Research Group,Memorial Sloan-Kettering Cancer Center.
The guide contains general information on opioid use in cancerpain, as well as specific dosing information on Dilaudid, includinga dose conversion chart. Call 201-575-5656 (9 am to 5 pm EST)for free copies.
Articles in this issue
over 30 years ago
First Results of Avicidin Trialsover 30 years ago
Chemo Patients Often Develop Menstrual Irregularitiesover 30 years ago
Growth Factor Receptor Blockade Moving From Laboratory to Clinicover 30 years ago
Controlled-Release AZT Gets FDA Go-Ahead for New Drug Investigationover 30 years ago
Vinorelbine Plus Chemo Promising in Advanced Diseaseover 30 years ago
Bone Substudy a Part of Tamoxifen Prevention Trialover 30 years ago
Ultrasound Breast Screens Useful in Selected Womenover 30 years ago
New Roles Forecast for Endocrine Therapyover 30 years ago
Antisense Drug Against BCL-2 Effective in Animal Cancer Modelsover 30 years ago
Anticancer Drugs From Zeneca in Regulatory Phase of DevelopmentNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.